Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's hopes of revolutionizing obesity treatment with its CagriSema drug have been cast into doubt following disappointing trial results, ...
Tag: CagriSema
News Summarized. Time Saved. Bite-sized news briefs for busy people. No fluff, just facts.